Circassia Pharmaceuticals (LON:CIR)‘s stock had its “buy” rating reaffirmed by stock analysts at Numis Securities in a report released on Monday. They currently have a GBX 180 ($2.42) price objective on the biopharmaceutical company’s stock. Numis Securities’ price target would indicate a potential upside of 83.58% from the company’s previous close.
Several other research firms have also weighed in on CIR. Peel Hunt reissued a “hold” rating and issued a GBX 130 ($1.75) price objective on shares of Circassia Pharmaceuticals in a research report on Tuesday, October 31st. J P Morgan Chase & Co lowered their price objective on Circassia Pharmaceuticals from GBX 120 ($1.62) to GBX 110 ($1.48) and set a “neutral” rating for the company in a research report on Thursday, September 28th.
Circassia Pharmaceuticals (LON CIR) opened at GBX 98.05 ($1.32) on Monday. Circassia Pharmaceuticals has a twelve month low of GBX 76.75 ($1.03) and a twelve month high of GBX 114 ($1.53).
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.
Receive News & Ratings for Circassia Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.